title: Insulin and endometrial cancer.
abstract: Elevated insulin levels may explain part of the increased risk of endometrial cancer observed in obese postmenopausal women. Circulating sex hormones and fasting C-peptide levels were measured in sera obtained from 165 postmenopausal endometrial cancer cases accrued between June 1, 1987, and May 15, 1990, from hospitals in Chicago, Illinois; Hershey, Pennsylvania; Irvine and Long Beach, California; Minneapolis, Minnesota; and Winston-Salem, North Carolina, and 180 community and hysterectomy controls. Women with a personal history of diabetes were excluded. Among controls, C-peptide was positively correlated with body mass index (BMI) ((r = 0.44), waist-to-thigh circumference ratio ((r = 0.24), estrone ((r = 0.18), and estradiol ((r = 0.28) (albumin-bound (r = 0.45), and free (r = 0.37)) and negatively correlated with sex hormone-binding globulin (r = -0.48). In age-adjusted analyses, the odds ratios and 95% confidence intervals for tertiles of C-peptide and endometrial cancer were, from lowest to highest: 1.0 (reference), 0.78 (95% confidence interval (CI) 0.43-1.4), and 2.2 (95% CI 1.3-3.7). Further adjustment for BMI substantially attenuated the odds ratios for the highest tertile of C-peptide (odds ratio = 1.2, 95% CI 0.63-2.1), and adjustment for body mass index and other risk factors for endometrial cancer eliminated the association (odds ratio = 1.0, 95% CI 0.55-2.0). In contrast, adjustment for C-peptide had little influence on the magnitude of the positive associations between body mass index (odds ratio for highest vs. lowest tertile, without and with adjustment for C-peptide = 4.1 (95% CI 2.3-7.5) and 3.7 (95% CI 1.9-7.1), respectively) or several steroid hormones and endometrial cancer. These data are not consistent with the hypothesis that the effect of obesity on endometrial cancer risk is mediated through high insulin levels.
authors.affiliation: Environmental Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892-7374, USA.
authors.forename: R
authors.initials: R
authors.lastname: Troisi
authors.forename: N
authors.initials: N
authors.lastname: Potischman
authors.forename: R N
authors.initials: RN
authors.lastname: Hoover
authors.forename: P
authors.initials: P
authors.lastname: Siiteri
authors.forename: L A
authors.initials: LA
authors.lastname: Brinton
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001824:Body Constitution; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D016889:Endometrial Neoplasms / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D008572:Menarche; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications; D016017:Odds Ratio; D010298:Parity; D012307:Risk Factors
chemical_list: D002096:C-Peptide; D003278:Contraceptives, Oral, Hormonal; D012739:Gonadal Steroid Hormones; D002784:Cholesterol